AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37115167 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate shocks delivered for ventricular fibrillation (VF) or wide complex rhythms ≥ 150/min
Number of subjects: 159
Study 37115167 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate shocks (narrow complex ≥ 150/min or wide complex 100-149/min)
Number of subjects: 159
Study 37115167 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate shocks delivered for asystole, sinus, narrow complex < 150/min, or wide complex < 100/min
Number of subjects: 159
Study 37115167 — intervention group
Group type: EXPERIMENTAL
Intervention: Shocks delivered in ICUs or emergency departments
Number of subjects: 159
Study 37115337 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 54
Study 37115337 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 54
Study 37115359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren plus standard of care (SoC)
Number of subjects: 307
Study 37115359 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 307
Study 37115464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 5-10 mg BID for 4 weeks, then 15 mg BID for 47 weeks, followed by tapering to once daily for 1 week.
Number of subjects: 210
Study 37115464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin treatment for CNePSCI, CPSP, and CNePPD.
Number of subjects: 210
Study 37115514 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (continuous dosing, 1 cycle = 28 days)
Number of subjects: 74
Study 37115514 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (continuous dosing)
Number of subjects: 74
Study 37115541 — intervention group
Group type: COMPARATOR
Intervention: DVD intervention
Number of subjects: 963
Study 37115541 — intervention group
Group type: COMPARATOR
Intervention: DVD/PN intervention
Number of subjects: 963
Study 37115541 — intervention group
Group type: COMPARATOR
Intervention: DVD group
Number of subjects: 963
Study 37115541 — intervention group
Group type: COMPARATOR
Intervention: DVD/PN group
Number of subjects: 963
Study 37115541 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 963
Study 37115590 — intervention group
Group type: EXPERIMENTAL
Intervention: Place-Based Permanent Supportive Housing (PB-PSH)
Number of subjects: 563
Study 37115590 — intervention group
Group type: EXPERIMENTAL
Intervention: Scatter-Site Permanent Supportive Housing (SS-PSH)
Number of subjects: 563
Study 37115610 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral economics-based incentives with anchoring strategy for meditation adherence
Number of subjects: 0
Study 37115610 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring messages for meditation tracking
Number of subjects: 0
Study 37115610 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for meditation at any time of day
Number of subjects: 0
Study 37115610 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for meditation performed at approximately the same time of day as personalized anchors
Number of subjects: 0
Study 37115620 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled coaching calls and gamified rewards
Number of subjects: 200
Study 37115620 — intervention group
Group type: COMPARATOR
Intervention: No scheduled coaching calls and gamified rewards
Number of subjects: 200
Study 37115620 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled coaching calls and flat rewards
Number of subjects: 200
Study 37115620 — intervention group
Group type: COMPARATOR
Intervention: No scheduled coaching calls and flat rewards
Number of subjects: 200
Study 37115632 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation procedure
Number of subjects: 101
Study 37115658 — intervention group
Group type: EXPERIMENTAL
Intervention: FAITH! Hypertension App
Number of subjects: 16
Study 37115724 — intervention group
Group type: COMPARATOR
Intervention: Personalised intervention
Number of subjects: 858
Study 37115807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruton's tyrosine kinase (BTK) and a proliferation-inducing ligand (APRIL) genes overexpression in patients with incident lymphoma (i-primary SS-NHL)
Number of subjects: 345
Study 37115807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruton's tyrosine kinase (BTK) expression
Number of subjects: 345
Study 37115807 — intervention group
Group type: COMPARATOR
Intervention: Transcriptomic analysis of 21 patients with primary SS-NHL
Number of subjects: 345
Study 37115905 — intervention group
Group type: EXPERIMENTAL
Intervention: INSTI-based first prescribed regimen
Number of subjects: 9094
Study 37115905 — intervention group
Group type: EXPERIMENTAL
Intervention: First ART discontinuation and reaching a first undetectable pVL
Number of subjects: 9094
Study 37115908 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical therapy plus growth hormone (GH) therapy
Number of subjects: 76
Study 37115908 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 76
Study 37115976 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 vaccination
Number of subjects: 809
Study 37115976 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on pandemic burden and vaccination hesitancy
Number of subjects: 809
Study 37116052 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic life events and stressors
Number of subjects: 230
Study 37116052 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression and anxiety of men under community supervision
Number of subjects: 230
Study 37116052 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner's substance use problems
Number of subjects: 230
Study 37116057 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation Therapy
Number of subjects: 0
Study 37116057 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37116228 — intervention group
Group type: EXPERIMENTAL
Intervention: Kukoamine B (KB) at doses of 0.06, 0.12, or 0.24 mg/kg every 8 hours for 7 days
Number of subjects: 44
Study 37116228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 37116228 — intervention group
Group type: EXPERIMENTAL
Intervention: Kukoamine B (KB)
Number of subjects: 44
Study 37116523 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib plus chemotherapy
Number of subjects: 539
Study 37116523 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 539
Study 37116523 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib
Number of subjects: 539
Study 37116523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539
Study 37116605 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels measured on days 0, 1, 2, 3, and 7
Number of subjects: 1105
Study 37116605 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels on days 2, 3, and 7
Number of subjects: 1105
Study 37116644 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week group-based intervention
Number of subjects: 360
Study 37116644 — intervention group
Group type: COMPARATOR
Intervention: Standard group-delivered PA comparison program
Number of subjects: 360
Study 37116645 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARE intervention (multicomponent communication intervention)
Number of subjects: 248
Study 37116645 — intervention group
Group type: COMPARATOR
Intervention: Minimally enhanced usual care (control)
Number of subjects: 248
Study 37116657 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycomacropeptide (GMP) supplementation
Number of subjects: 13
Study 37116658 — intervention group
Group type: EXPERIMENTAL
Intervention: TX Sprouts intervention (gardening, cooking, and nutrition education)
Number of subjects: 468
Study 37116658 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed intervention)
Number of subjects: 468
Study 37116658 — intervention group
Group type: EXPERIMENTAL
Intervention: TX Sprouts intervention (gardening, cooking, and nutrition education) among Hispanic children
Number of subjects: 468
Study 37116714 — intervention group
Group type: EXPERIMENTAL
Intervention: 'One-stop-shop' point-of-care HCV RNA testing intervention
Number of subjects: 540
Study 37116714 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 540
Study 37116746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing laparoscopic resection for RSE
Number of subjects: 3050
Study 37116825 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (600 mg Theracurmin HP daily for 30 days)
Number of subjects: 58
Study 37116825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 30 days)
Number of subjects: 58
Study 37116952 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive staging surgery without lymphadenectomy
Number of subjects: 656
Study 37116952 — intervention group
Group type: COMPARATOR
Intervention: Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy
Number of subjects: 656
Study 37116972 — intervention group
Group type: EXPERIMENTAL
Intervention: isCGM
Number of subjects: 945
Study 37117001 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month multidomain intervention programme including cognitive training, physical exercise, nutrition, psychoeducation, and assessment/correction of hearing loss.
Number of subjects: 70
Study 37117001 — intervention group
Group type: COMPARATOR
Intervention: Usual standard of care provided to these diseases.
Number of subjects: 70
Study 37117085 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous intervention (CTO-PCI)
Number of subjects: 0
Study 37117085 — intervention group
Group type: COMPARATOR
Intervention: Pharmaceutical therapy
Number of subjects: 0
Study 37117153 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 3067
Study 37117153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure
Number of subjects: 3067
Study 37117153 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid
Number of subjects: 3067
Study 37117153 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosylated haemoglobin (HbA1c)
Number of subjects: 3067
Study 37117153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein(a)
Number of subjects: 3067
Study 37117153 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-C)
Number of subjects: 3067
Study 37117153 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model including risk factors
Number of subjects: 3067
Study 37117201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 13
Study 37117201 — intervention group
Group type: COMPARATOR
Intervention: Individualized relapse-based approach
Number of subjects: 13
Study 37117213 — intervention group
Group type: EXPERIMENTAL
Intervention: MasitinibL
Number of subjects: 0
Study 37117213 — intervention group
Group type: COMPARATOR
Intervention: Masitinib
Number of subjects: 0
Study 37117993 — intervention group
Group type: EXPERIMENTAL
Intervention: Model combining tau phosphorylated at threonine 181 (P-tau181) and neurofilament light (NfL)
Number of subjects: 573
Study 37117993 — intervention group
Group type: COMPARATOR
Intervention: Plasma biomarkers of β-amyloid (Aβ)
Number of subjects: 573
Study 37118058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (TRYP) 6g
Number of subjects: 69
Study 37118058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 37118158 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Volar Approach (SVA)
Number of subjects: 106
Study 37118158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronator-Sparing Approach (PqSA)
Number of subjects: 106
Study 37118334 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially de-epithelialized free gingival grafts (d-FGGs)
Number of subjects: 15
Study 37118334 — intervention group
Group type: COMPARATOR
Intervention: Conventional free gingival grafts (FGGs)
Number of subjects: 15
Study 37118696 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough desensitization treatment (CDT)
Number of subjects: 21
Study 37118696 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 21
Study 37118703 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated cTnT (≥ 14 ng/L) one year after the primary event
Number of subjects: 1278
Study 37118703 — intervention group
Group type: COMPARATOR
Intervention: Low cTnT after the primary event
Number of subjects: 1278
Study 37118707 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 30
Study 37118707 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone injection
Number of subjects: 30
Study 37118803 — intervention group
Group type: EXPERIMENTAL
Intervention: Furmonertinib 40 mg orally once daily
Number of subjects: 132
Study 37118803 — intervention group
Group type: EXPERIMENTAL
Intervention: Furmonertinib 80 mg orally once daily
Number of subjects: 132
Study 37118803 — intervention group
Group type: EXPERIMENTAL
Intervention: Furmonertinib 160 mg orally once daily
Number of subjects: 132
Study 37118803 — intervention group
Group type: EXPERIMENTAL
Intervention: Furmonertinib 240 mg orally once daily
Number of subjects: 132
Study 37118818 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy with bilateral prophylactic central neck dissection and adjuvant RAI 30 mCi
Number of subjects: 598
Study 37118818 — intervention group
Group type: COMPARATOR
Intervention: Total thyroidectomy alone
Number of subjects: 598
Study 37118832 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (BMMNC) infusion
Number of subjects: 11
Study 37118904 — intervention group
Group type: EXPERIMENTAL
Intervention: Telomere-Shortest-Length-Assay (TeSLA)
Number of subjects: 352
Study 37118904 — intervention group
Group type: COMPARATOR
Intervention: Southern blotting (SB)
Number of subjects: 352
Study 37119051 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (enza) + Leuprolide Acetate (LA) 160 mg/day
Number of subjects: 1068
Study 37119051 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide monotherapy (mono)
Number of subjects: 1068
Study 37119051 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Leuprolide Acetate (LA)
Number of subjects: 1068
Study 37119056 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR445088 in SOC-Treated group
Number of subjects: 90
Study 37119056 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR445088 in SOC-Refractory group
Number of subjects: 90
Study 37119056 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR445088 in SOC-Naïve group
Number of subjects: 90
Study 37119056 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR445088 during 12-week overlapping period in SOC-Treated group
Number of subjects: 90
Study 37119056 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR445088 in Part B
Number of subjects: 90
Study 37119064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4304
Study 37119064 — intervention group
Group type: COMPARATOR
Intervention: Control (no dapagliflozin)
Number of subjects: 4304
Study 37119067 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 5231
Study 37119067 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 5231
Study 37119067 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Stenosis (AS)
Number of subjects: 5231
Study 37119080 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR) on clopidogrel (≥252 P2Y12 reactivity units) in men
Number of subjects: 11714
Study 37119080 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR) on clopidogrel (≥252 P2Y12 reactivity units) in women
Number of subjects: 11714
Study 37119080 — intervention group
Group type: COMPARATOR
Intervention: Control group (men without HPR)
Number of subjects: 11714
Study 37119080 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without HPR)
Number of subjects: 11714
Study 37119085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance assessment
Number of subjects: 2175
Study 37119085 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary acute kidney injury (AKI)
Number of subjects: 2175
Study 37119094 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB)
Number of subjects: 0
Study 37119094 — intervention group
Group type: COMPARATOR
Intervention: Non-SGB (control group)
Number of subjects: 0
Study 37119097 — intervention group
Group type: EXPERIMENTAL
Intervention: ICPinf monitoring
Number of subjects: 15
Study 37119097 — intervention group
Group type: EXPERIMENTAL
Intervention: ICPinf burden
Number of subjects: 15
Study 37119097 — intervention group
Group type: COMPARATOR
Intervention: ICPsup
Number of subjects: 15
Study 37119186 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary care unit patients
Number of subjects: 0
Study 37119186 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharged patients
Number of subjects: 0
Study 37119186 — intervention group
Group type: EXPERIMENTAL
Intervention: New coronary care unit mortality score
Number of subjects: 0
Study 37119208 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadest definition of relapse
Number of subjects: 0
Study 37119208 — intervention group
Group type: EXPERIMENTAL
Intervention: PIRA (6-month confirmed disability worsening without relapse)
Number of subjects: 0
Study 37119208 — intervention group
Group type: EXPERIMENTAL
Intervention: PIA (progression independent of any inflammatory activity)
Number of subjects: 0
Study 37119208 — intervention group
Group type: EXPERIMENTAL
Intervention: Two CDW events (not relapse)
Number of subjects: 0
Study 37119264 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded retainer 13-23
Number of subjects: 90
Study 37119264 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded retainer 12-22
Number of subjects: 90
Study 37119264 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable vacuum-formed retainer
Number of subjects: 90
Study 37119314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib plus pegylated interferon-α2b
Number of subjects: 0
Study 37119314 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study 37119322 — intervention group
Group type: EXPERIMENTAL
Intervention: HPI guided GDT protocol
Number of subjects: 60
Study 37119322 — intervention group
Group type: COMPARATOR
Intervention: Control group (GDT protocol aimed at SVI optimization)
Number of subjects: 60
Study 37119480 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable isotope labeling paired with mass spectrometry to evaluate in vivo protein kinetics and concentration of soluble SOD1 in cerebrospinal fluid (CSF).
Number of subjects: 0
Study 37119480 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of deaminated SOD1 peptide, SDGPVKV, correlating with protein stability.
Number of subjects: 0
Study 37119480 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable isotope labeling approaches and peptide deamidation.
Number of subjects: 0
Study 37119510 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for gastric, duodenal, ampullary and rectal pouch polyps
Number of subjects: 0
Study 37119510 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemopreventive therapies targeting FAP
Number of subjects: 0
Study 37119510 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and non-steroidal anti-inflammatories (NSAIDs)
Number of subjects: 0
Study 37119510 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic management
Number of subjects: 0
Study 37119510 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary use of chemopreventive agents and endoscopic therapy
Number of subjects: 0
Study 37119523 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 (trastuzumab emtansine)
Number of subjects: 284
Study 37119829 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary DKK3 above the median (>1689 pg/mg creatinine)
Number of subjects: 659
Study 37119829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified blood pressure control in children with urinary DKK3 >1689 pg/mg creatinine
Number of subjects: 659
Study 37119829 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of the renin-angiotensin-aldosterone system
Number of subjects: 659
Study 37119868 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment for depression and smoking (12-week intervention)
Number of subjects: 300
Study 37119871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nummular Eczema (NE)
Number of subjects: 50
Study 37120027 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine radiation therapy with LLNs inside the clinical target volume (CTV)
Number of subjects: 223
Study 37120027 — intervention group
Group type: COMPARATOR
Intervention: Routine radiation therapy with LLNs outside the clinical target volume (CTV)
Number of subjects: 223
Study 37120027 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine radiation therapy with LLNs receiving ≥95% of planned dose
Number of subjects: 223
Study 37120027 — intervention group
Group type: COMPARATOR
Intervention: Routine radiation therapy with LLNs receiving <95% of planned dose
Number of subjects: 223
Study 37120027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation of 60 Gy
Number of subjects: 223
Study 37120031 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulevirtide (BLV) monotherapy
Number of subjects: 21
Study 37120135 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical related donor bone marrow transplantation (haplo-BMT)
Number of subjects: 368
Study 37120135 — intervention group
Group type: COMPARATOR
Intervention: Unrelated umbilical cord blood transplantation (UCBT)
Number of subjects: 368
Study 37120136 — intervention group
Group type: EXPERIMENTAL
Intervention: Omidubicel
Number of subjects: 37
Study 37120136 — intervention group
Group type: COMPARATOR
Intervention: Standard UCB
Number of subjects: 37
Study 37120460 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAT Cancer intervention
Number of subjects: 222
Study 37120460 — intervention group
Group type: COMPARATOR
Intervention: Written materials (control)
Number of subjects: 222
Study 37120509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Medication Therapy Management (pMTM) intervention
Number of subjects: 296
Study 37120509 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 296
Study 37120522 — intervention group
Group type: EXPERIMENTAL
Intervention: CNV analysis in mGluR network genes
Number of subjects: 15689